4D Molecular Therapeutics, Inc. NASDAQ:FDMT

Founder-led company

4D Molecular Therapeutics stock price today

$6.52
+0.96
+17.48%
Financial Health
0
1
2
3
4
5
6
7
8
9

4D Molecular Therapeutics stock price monthly change

-79.61%
month

4D Molecular Therapeutics stock price quarterly change

-79.61%
quarter

4D Molecular Therapeutics stock price yearly change

-73.70%
year

4D Molecular Therapeutics key metrics

Market Cap
272.05M
Enterprise value
472.01M
P/E
-5.08
EV/Sales
250.93
EV/EBITDA
-3.04
Price/Sales
270.19
Price/Book
2.19
PEG ratio
0.17
EPS
-2.5
Revenue
20.45M
EBITDA
-116.39M
Income
-104.55M
Revenue Q/Q
-90.60%
Revenue Y/Y
826.68%
Profit margin
-8608.08%
Oper. margin
-8763.96%
Gross margin
0%
EBIT margin
-8763.96%
EBITDA margin
-569.11%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

4D Molecular Therapeutics stock price history

4D Molecular Therapeutics stock forecast

4D Molecular Therapeutics financial statements

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Profit margin
Jun 2023 239K -29.61M -12391.63%
Sep 2023 20.20M -10.25M -50.76%
Dec 2023 -19K -32.28M 169910.53%
Mar 2024 28K -32.40M -115717.86%
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Analyst Estimates
Mar 2024 28K -32.40M -115717.86%
Sep 2025 500K -35.21B -7043412.06%
Oct 2025 500K -49.76M -9952.94%
Dec 2025 500K -53.21M -10642.75%
  • Analysts Price target

  • Financials & Ratios estimates

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Debt to assets
Jun 2023 352503000 725.29M 205.75%
Sep 2023 361613000 31.67M 8.76%
Dec 2023 339891000 32.06M 9.43%
Mar 2024 629884000 29.32M 4.66%
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Cash Flow
Jun 2023 -22.06M 49.28M 130.51M
Sep 2023 -1.17M 29.98M 10.55M
Dec 2023 -24.65M -6.68M 4.76M
Mar 2024 -29.08M -263.25M 318.83M

4D Molecular Therapeutics alternative data

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Employee count
Aug 2023 137
Sep 2023 137
Oct 2023 137
Nov 2023 137
Dec 2023 144
Jan 2024 144
Feb 2024 144
Mar 2024 147
Apr 2024 147
May 2024 147
Jun 2024 171
Jul 2024 171

4D Molecular Therapeutics other data

77.55% -3.30%
of FDMT is owned by hedge funds
25.06M -993.41K
shares is hold by hedge funds

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 614665
Feb 2024 0 104208
Mar 2024 0 7583
Apr 2024 0 9903
May 2024 0 1750
Jun 2024 0 14680
Jul 2024 0 20917
Aug 2024 0 500
Sep 2024 0 500
Transaction Date Insider Security Shares Price per share Total value Source
Option
BIZILY SCOTT officer: Chief Legal Officer
Stock Option (Right To Buy) 500 $6.49 $3,245
Option
BIZILY SCOTT officer: Chief Legal Officer
Common Stock 500 $6.49 $3,245
Sale
BIZILY SCOTT officer: Chief Legal Officer
Common Stock 500 $16.33 $8,165
Option
BIZILY SCOTT officer: Chief Legal Officer
Stock Option (Right To Buy) 500 $6.49 $3,245
Option
BIZILY SCOTT officer: Chief Legal Officer
Common Stock 500 $6.49 $3,245
Sale
BIZILY SCOTT officer: Chief Legal Officer
Common Stock 500 $15 $7,500
Option
BIZILY SCOTT officer: Chief Legal Officer
Stock Option (Right To Buy) 1,250 $8.04 $10,050
Option
BIZILY SCOTT officer: Chief Legal Officer
Stock Option (Right To Buy) 500 $6.49 $3,245
Option
BIZILY SCOTT officer: Chief Legal Officer
Common Stock 1,250 $8.04 $10,050
Option
BIZILY SCOTT officer: Chief Legal Officer
Common Stock 500 $6.49 $3,245
Wednesday, 13 November 2024
zacks.com
globenewswire.com
Monday, 4 November 2024
accesswire.com
Sunday, 3 November 2024
accesswire.com
Saturday, 2 November 2024
accesswire.com
Sunday, 27 October 2024
accesswire.com
Saturday, 26 October 2024
accesswire.com
Sunday, 20 October 2024
accesswire.com
Saturday, 19 October 2024
accesswire.com
Friday, 18 October 2024
accesswire.com
Thursday, 17 October 2024
accesswire.com
Tuesday, 15 October 2024
accesswire.com
Monday, 14 October 2024
accesswire.com
Sunday, 13 October 2024
accesswire.com
Saturday, 12 October 2024
accesswire.com
Friday, 11 October 2024
accesswire.com
Thursday, 10 October 2024
accesswire.com
Wednesday, 9 October 2024
accesswire.com
Tuesday, 8 October 2024
accesswire.com
Monday, 7 October 2024
accesswire.com
Sunday, 6 October 2024
accesswire.com
Saturday, 5 October 2024
accesswire.com
Friday, 4 October 2024
seekingalpha.com
accesswire.com
Thursday, 3 October 2024
accesswire.com
Wednesday, 2 October 2024
accesswire.com
Tuesday, 1 October 2024
accesswire.com
Monday, 30 September 2024
accesswire.com
Sunday, 29 September 2024
accesswire.com
Saturday, 28 September 2024
accesswire.com
  • What's the price of 4D Molecular Therapeutics stock today?

    One share of 4D Molecular Therapeutics stock can currently be purchased for approximately $6.52.

  • When is 4D Molecular Therapeutics's next earnings date?

    Unfortunately, 4D Molecular Therapeutics's (FDMT) next earnings date is currently unknown.

  • Does 4D Molecular Therapeutics pay dividends?

    No, 4D Molecular Therapeutics does not pay dividends.

  • How much money does 4D Molecular Therapeutics make?

    4D Molecular Therapeutics has a market capitalization of 272.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 562.29% to 20.72M US dollars.

  • What is 4D Molecular Therapeutics's stock symbol?

    4D Molecular Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FDMT".

  • What is 4D Molecular Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of 4D Molecular Therapeutics?

    Shares of 4D Molecular Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are 4D Molecular Therapeutics's key executives?

    4D Molecular Therapeutics's management team includes the following people:

    • Dr. David H. Kirn Co-Founder, Chief Executive Officer, Pres & Director(age: 62, pay: $701,530)
    • Mr. August J. Moretti Esq., J.D. Chief Financial Officer(age: 74, pay: $632,760)
    • Dr. Robert S. Fishman Chief Medical Officer & Therapeutic Area Head of Pulmonology(age: 63, pay: $184,620)
    • Dr. David E. Schaffer Ph.D. Co-Founder, Chief Scientific Advisor & Independent Director(age: 55, pay: $108,380)
    • Dr. John F. Milligan Executive Chairman(age: 64, pay: $55,840)
  • Is 4D Molecular Therapeutics founder-led company?

    Yes, 4D Molecular Therapeutics is a company led by its founders Dr. David H. Kirn and Dr. David E. Schaffer Ph.D..

  • How many employees does 4D Molecular Therapeutics have?

    As Jul 2024, 4D Molecular Therapeutics employs 171 workers, which is 16% more then previous quarter.

  • When 4D Molecular Therapeutics went public?

    4D Molecular Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 11 Dec 2020.

  • What is 4D Molecular Therapeutics's official website?

    The official website for 4D Molecular Therapeutics is 4dmoleculartherapeutics.com.

  • Where are 4D Molecular Therapeutics's headquarters?

    4D Molecular Therapeutics is headquartered at 5858 Horton Street, EmeryVille, CA.

  • How can i contact 4D Molecular Therapeutics?

    4D Molecular Therapeutics's mailing address is 5858 Horton Street, EmeryVille, CA and company can be reached via phone at +51 05052680.

4D Molecular Therapeutics company profile:

4D Molecular Therapeutics, Inc.

4dmoleculartherapeutics.com
Exchange:

NASDAQ

Full time employees:

147

Industry:

Biotechnology

Sector:

Healthcare

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

5858 Horton Street
EmeryVille, CA 94608

CIK: 0001650648
ISIN: US35104E1001
CUSIP: 35104E100